ARTICLE | Clinical News
Telik begins Phase II
March 27, 2001 8:00 AM UTC
TELK began an open-label, U.S. Phase II study of its TLK286, a nitrogen mustard alkylating agent prodrug activated by glutathione S-transferase P1-1 (GSTP1-1), in 75 refractory colon cancer patients. ...